MedTech Revolution: Nest Health and DocPace

The MedTech Startup Revolution: How Companies Like Nest Health and Docpace Are Reshaping Healthcare - And Why Investors Are Paying Attention

How early-stage ventures born in underserved markets are leading a national medtech transformation, and what the venture capital community is betting on next.

A Sector in Transition

The medical technology startup landscape in 2026 is defined by a striking paradox: more money than ever is flowing into the sector, but into fewer hands. In the first quarter of 2026 alone, digital health startups raised $4 billion across just 110 deals - up from $3 billion across 122 deals in Q1 2025 - with nearly 60% of that capital concentrated in a dozen mega-rounds exceeding $100 million. Total global healthcare venture financing hit $60.4 billion in 2025, a 4% year-over-year jump, but the deal count tells a different story: investors are consolidating bets on proven, scalable platforms rather than sprinkling seed checks across moonshots.

This "flight to quality" has reshaped the conversation around what makes a medtech startup investable. Clinical validation, payer alignment, AI-enabled workflows, and - critically - a demonstrable impact on real-world health outcomes have become the new table stakes. Amid this shift, two companies from Louisiana's burgeoning Gulf Coast startup ecosystem offer a compelling case study in where medtech innovation is heading: Nest Health and Docpace, both portfolio companies of Callais Capital Management, a venture capital firm rooted in four generations of entrepreneurial experience along the Third Coast.

Nest Health: Bringing the Clinic Home to America's Most Vulnerable Families

Few statistics capture the urgency of healthcare reform as starkly as these: Louisiana ranks 49th in child well-being. Thirty-nine out of every 100,000 mothers in the state die during or shortly after childbirth. The March of Dimes gave Louisiana an "F" grade for maternal and infant health outcomes. And more US counties have become maternity care deserts since 2020.

Nest Health was born to confront this crisis. Co-founded in 2021 by Dr. Rebekah Gee - a practicing obstetrician-gynecologist, mother of five, and former Louisiana Secretary of Health - and Rebecca Kavoussi, former president of Landmark Health, the New Orleans-based startup is the first value-based healthcare provider built for the whole family.

The model is deceptively simple but radically different: Nest deploys local care teams into patients' homes, delivering primary care, mental health and substance use disorder treatment, housing and utilities assistance, developmental screenings, vaccinations, and 24/7 virtual clinical access - all at no additional cost to families covered by participating Medicaid plans. By treating the family as a unit rather than as isolated patients scattered across specialists, Nest eliminates the transportation barriers, fragmented referrals, and appointment chaos that keep underserved families from receiving care.

The results speak volumes. Nest Health reports a 60% reduction in emergency room utilization in Louisiana and vaccination rates twice the state's target benchmark - even as 2024 CDC data shows Louisiana among the lowest states nationally for routine childhood and flu immunizations. From a modest patient base in 2023, Nest has scaled to 12,000 patients across the Capital Region and Greater New Orleans and 18,000 patients in Arizona, where it launched in June 2025. Expansion is now underway into eight additional states.

Financially, the startup's trajectory has been equally impressive. After a $15 million seed round led by 8VC and Blue Venture Fund in 2023, a $4 million seed extension led by SpringTide in 2024, and a $22.5 million Series A - which brought in impact-focused investors like Socium Ventures (backed by Cox Enterprises), Impact America Fund, Amboy Street Ventures, Hopelab, and Luminary Impact Fund - Nest Health is now backed by more than $50 million in total funding. Fast Company recognized the company on both its "World Changing Ideas" and "Most Innovative Healthcare Companies" lists in 2025.

"Nest has demonstrated that bringing care directly into the home can help improve health outcomes and cost savings," said Tim Howe, partner at Socium Ventures. "The team's unique combination of clinical acumen and technology expertise positions them to scale this impact nationwide."

Docpace: Using AI to Fix Healthcare's Most Persistent Bottleneck

If Nest Health addresses where and how care is delivered, Docpace tackles the equally stubborn problem of when - specifically, the billion-dollar inefficiency of patient scheduling.

Founded by Shelby Sanderford Dabelich, Docpace is a Metairie, Louisiana-based health tech company offering the only patented AI-powered schedule optimization solution in healthcare. The platform integrates directly with electronic medical record systems like athenahealth, working in real time to alert practices of scheduling inefficiencies, send personalized reminders to patients, predict no-shows using machine learning, and dynamically adjust appointment times to keep the day running at full capacity.

The problem Docpace solves is deceptively enormous. Patient no-shows cost the U.S. healthcare system an estimated $150 billion annually, while the average American spends excessive time in waiting rooms - a primary driver of patient dissatisfaction and, ultimately, disengagement from the healthcare system. For providers, idle time between patients translates directly into lost revenue and underutilized clinical capacity.

Docpace's AI-driven approach has produced measurable results: a 25% reduction in no-shows, an average of 30 minutes of staff time saved per day through streamlined patient flow, and an additional $1,900 in monthly revenue per provider by filling schedule gaps and ensuring more appointments are kept. As Sanderford Dabelich describes it, the platform aligns the historically competing interests of providers (who want to see more patients) and patients (who want to be seen on time) - a true win-win that requires no additional workload from either side.

The company gained early traction after winning a pitch competition hosted by The Idea Village, New Orleans' prominent startup accelerator, in 2020 and has since grown to a team of 20. A landmark partnership with Access Health Louisiana - a statewide network of federally qualified health centers serving more than 60,000 patients across 16 parishes - validated Docpace's scalability in complex, multi-location clinical environments.

"Docpace allows our operations team to view productivity data by clinical location and by provider in real-time," noted Chenier Reynolds, VP at Access Health Louisiana - a capability that is increasingly critical as healthcare organizations pursue data-driven management.

Where These Companies Intersect: The New Medtech Thesis

Nest Health and Docpace might seem like very different businesses - one provides in-home primary care, the other optimizes provider schedules - but they share a DNA that reflects the most compelling trends in medtech investing:

1. AI as Infrastructure, Not Novelty: Both companies embed artificial intelligence deep within their operational workflows. Nest uses AI to automate care coordination, triage patient needs, and enable its teams to operate efficiently at scale. Docpace uses predictive analytics and real-time data to transform a fundamentally analog process - scheduling - into an intelligent, self-optimizing system. In 2026, investors are no longer funding AI as a buzzword; they're funding AI that demonstrably improves unit economics and clinical throughput.

1. Value-Based Care Alignment: The industry's shift from fee-for-service to value-based care models is not a trend - it's a mandate. Nest Health's entire business model is built around value-based reimbursement through Medicaid managed care plans. Docpace enables practices to maximize throughput within value-based frameworks by eliminating waste. Investors increasingly evaluate startups on their alignment with payer incentives, and both companies score highly.

1. Addressing Access in Underserved Markets: Perhaps most importantly, both Nest Health and Docpace were forged in one of the most underserved healthcare markets in the country. Louisiana's dismal maternal health outcomes and care deserts aren't abstract policy talking points to these founders - they're lived realities that informed the product from day one. This gives both companies credibility that pure technology plays often lack.

How Investors and Venture Capital Firms Are Thinking About MedTech in 2026

The venture capital landscape for medtech and digital health has undergone what Silicon Valley Bank calls a "structural reset." Several clear themes dominate investor thinking:

The "Flight to Quality"

According to PitchBook's 2025 reports, investors are increasingly prioritizing mature, AI-enabled platforms with scalable models, interoperability with existing clinical workflows, and strong payer alignment. Series B and later rounds now dominate the funding landscape, and the bar for early-stage companies has risen dramatically. Startups must arrive at the fundraising table with real-world clinical validation, not just prototypes.

This is precisely the environment where companies like Nest Health - which can point to a 60% ER reduction and rapid patient growth across two states - and Docpace - with patented technology and quantifiable ROI per provider - become standout investments.

Corporate Venture Arms Are Back

Major industry incumbents are deploying capital more aggressively than at any point in the past five years. Medtronic Ventures, Johnson & Johnson Innovation (JJDC), and Philips Ventures have all increased allocations to early-stage healthtech, using their venture arms as strategic filters to identify future M&A targets. JPMorgan's 2024 MedTech Industry Insights report noted a 12% increase in venture dollars even as total deal counts fell - a clear signal of strategic concentration.

For startups, this means the acqui-hire and strategic acquisition pathway is more viable than ever. Companies that can integrate seamlessly into large health system or payer workflows have a natural exit ramp.

Impact Investing Goes Mainstream

Nest Health's investor roster - which includes Impact America Fund, Hopelab, and Luminary Impact Fund alongside traditional venture firms like 8VC - illustrates a broader trend: impact investing and commercial returns are no longer seen as mutually exclusive in healthcare. Firms focused on underserved populations, women's health, and underrepresented geographies (like Town Hall Ventures, Foreground Capital, and SoGal Ventures) are deploying meaningful capital.

"Amboy Street Ventures invests in companies that fundamentally expand access to care for women and families," noted investor Carli Sapir. The thesis is clear: companies that solve for equity and economics will capture the largest addressable markets.

Regional VC Is Having Its Moment

The success of Gulf Coast-born companies like Nest Health and Docpace also validates a growing conviction among investors that the next generation of transformative startups doesn't have to come from Silicon Valley or Boston. Firms like Callais Capital Management - headquartered in Louisiana, backed by 66+ years of entrepreneurial legacy, and armed with 34+ venture investments - are proving that deep regional knowledge, operational support, and aligned capital (the Callais family co-invests 10% alongside external investors) can surface world-class startups that coastal funds might overlook.

"Empowering growth through Gulf Coast venture capital investments by leveraging four generations of entrepreneurial expertise to provide capital and operational support to early-stage companies in an underserved regional market" isn't just Callais Capital's mission statement - it's a thesis that the broader market is now embracing.

Looking Ahead: What 2026 and Beyond Hold

The medtech investment trajectory points toward several developments:

• IPO Activity Will Accelerate. Policy uncertainty pushed healthtech IPOs from 2025 into 2026, but the window is opening. PitchBook projects that startups with strong commercial traction will begin testing public markets again this year.

• M&A Will Intensify. M&A activity surged 61% in 2025, with headline deals like Stryker's $4.9 billion acquisition of Inari Medical signaling appetite for scaled medtech platforms. Startups with proven clinical and operational outcomes will be prime targets.

• Mega-Deals Will Dominate. If current trends hold, 2026 could see 50 or more funding rounds exceeding $100 million - concentrating capital further among the sector's most promising players.

• In-Home and Community-Based Care Will Scale Nationally. Nest Health's expansion blueprint - from a single New Orleans market to two states and eyeing eight more - is a microcosm of the broader push toward decentralized, home-based care delivery, particularly for Medicaid populations.

• AI-Driven Operational Tools Will Become Table Stakes. Just as EHRs became mandatory infrastructure over the past decade, AI-powered scheduling, triage, and workflow optimization tools like Docpace will become expected components of any modern clinical operation.

The Bottom Line

The medtech startup landscape of 2026 rewards companies that combine technological sophistication with tangible clinical impact - and punishes those that can only offer one or the other. Nest Health and Docpace exemplify the dual mandate: both were built to solve specific, painful problems in healthcare delivery; both leverage AI as a means rather than an end; and both were incubated in one of the most challenging healthcare environments in the country.

For investors and venture capital firms, the lesson is equally clear: the greatest opportunities in medtech may not come from well-trodden innovation hubs, but from the communities where the need is most acute. Firms like Callais Capital Management - with their deep roots in the Third Coast, multi-generational operating experience, and commitment to backing founders who build for the underserved - are positioned not just to participate in the medtech revolution, but to lead it from the front.

Tempered by the past. Built for the future, indeed.

Sources include reporting from Fierce Healthcare, MedTech Dive, PitchBook, Biz New Orleans, Behavioral Health Business, Rock Health, Silicon Valley Bank, and company disclosures from Nest Health, Docpace, and Callais Capital Management.